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Aims Heart failure with preserved ejection fraction (HFpEF) is increasingly common but there is currently no established
pharmacological therapy. We hypothesized that ORM-11035, a novel specific Na+/Ca2+ exchanger (NCX) inhibitor,
improves cardiac function and remodelling independent of effects on arterial blood pressure in a model of cardiorenal
HFpEF.
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Methods
and results
Rats were subjected to subtotal nephrectomy (NXT) or sham operation. Eight weeks after intervention, treatment
for 16weeks with ORM-11035 (1 mg/kg body weight) or vehicle was initiated. At 24weeks, blood pressure mea-
surements, echocardiography and pressure–volume loops were performed. Contractile function, Ca2+ transients
and NCX-mediated Ca2+ extrusion were measured in isolated ventricular cardiomyocytes. NXT rats (untreated)
showed a HFpEF phenotype with left ventricular (LV) hypertrophy, LV end-diastolic pressure (LVEDP) elevation,
increased brain natriuretic peptide (BNP) levels, preserved ejection fraction and pulmonary congestion. In cardiomy-
ocytes from untreated NXT rats, early relaxation was prolonged and NCX-mediated Ca2+ extrusion was decreased.
Chronic treatment with ORM-11035 significantly reduced LV hypertrophy and cardiac remodelling without lower-
ing systolic blood pressure. LVEDP [14± 3 vs. 9 ± 2mmHg; NXT (n = 12) vs. NXT+ORM (n =12); P = 0.0002]
and BNP levels [71± 12 vs. 49±11 pg/mL; NXT (n =12) vs. NXT+ORM (n =12); P < 0.0001] were reduced after
ORM treatment. LV cardiomyocytes from ORM-treated rats showed improved active relaxation and diastolic cytoso-
lic Ca2+ decay as well as restored NCX-mediated Ca2+ removal, indicating NCX modulation with ORM-11035 as a
promising target in the treatment of HFpEF.
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Conclusion Chronic inhibition of NCX with ORM-11035 significantly attenuated cardiac remodelling and diastolic dysfunction
without lowering systemic blood pressure in this model of HFpEF. Therefore, long-term treatment with selective
NCX inhibitors such as ORM-11035 should be evaluated further in the treatment of heart failure.
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Keywords Na+/Ca2+ exchanger • ORM-11035 • Heart failure with preserved ejection fraction •
Cardiomyocyte • Calcium
*Corresponding author. Department of Cardiology, Charité-University Medicine Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. Tel: +49 30
450553702, Fax: +49 30 4507553702, Email: frank.heinzel@charite.de
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1544 U. Primessnig et al.
Introduction
Heart failure (HF) is increasingly common in the general popu-
lation implicating a considerable socioeconomic burden. A large
number of patients with signs and symptoms of HF present with
structurally remodelled hearts but a preserved ejection fraction
(HFpEF). HFpEF is regarded as a heterogeneous clinical syndrome
with different aetiologies.1 Common clinical risk factors for HFpEF
include arterial hypertension, diabetes and renal failure. Currently,
no pharmacological therapy has been proven effective in improv-
ing prognosis in HFpEF patients. Recently, we have reported a
cardiorenal model of HFpEF in rats, which mimics many of the
features that define the clinical HFpEF syndrome.2 Parameters
of HF in vivo correlated with impaired relaxation of cardiomy-
ocytes and slowed decay of the intracellular Ca2+ transient. In this
model, chronic inhibition of the Na+/Ca2+ exchanger (NCX) with
SEA0400 improved diastolic function and cardiac remodelling in
vitro and in vivo, suggesting a role of increased reverse-mode NCX
activity (Ca2+ import). However, while treatment with SEA0400
improved relaxation, it was associated with a reduction in sys-
temic blood pressure, likely related to SEA0400 inhibitory effects
on L-type Ca2+ channels.2 In the present study, we employed a
novel NCX inhibitor, ORM-11035, to investigate whether a more
specific NCX inhibition confirms the role of the NCX in this model
of HFpEF and may improve cardiac function and remodelling with-
out lowering systemic blood pressure.
Methods
All experiments were approved by the local Ethics Committee (GZ:
BMWF-66.010/0040-II/3b/2012) and performed in agreement with the
Guidelines for the Care and Use of Laboratory Animals (National
Institutes of Health, USA). Animals were housed in a 12 h light/dark
regime under conventional conditions in the local animal facility with
free access to food and water. Experiments were performed as previ-
ously described.2 Forty young male 8-week old Wistar rats (HsdRC-
CHan, Harlan, Italy) with a body weight between 250 and 275 g under-
went subtotal (5/6) nephrectomy (NXT) or sham operation (Sham)
in a one-time intervention.3 Animals were observed for 24weeks
post-operatively. Non-invasive blood pressure measurements were
performed weekly (tail-cuff method). Treatment with ORM-11035
(1 mg/kg body weight/day divided into two daily doses) or vehi-
cle via oral gavage was performed starting 8weeks post-surgery for
16weeks including the day of final experiment. At 24weeks transtho-
racic echocardiography was performed in anaesthetized rats with heart
rate continuously measured by electrocardiographic electrodes. Mea-
surements were performed to assess changes in cardiac function and
dimensions from at least three consecutive cardiac cycles under sta-
ble conditions using standard formulas. Invasive haemodynamic mea-
surements (pressure–volume loops) were performed as previously
described. The pressure–volume conductance catheter (SPR-838, Mil-
lar Instruments, Houston, TX, USA) was inserted into the right carotid
artery and advanced into the ascending aorta and then into the left ven-
tricle. Parameters of systolic and diastolic function including left ven-
tricular (LV) end-systolic pressure, LV end-diastolic pressure (LVEDP),
LV end-systolic volume, LV end-diastolic volume, stroke volume, car-
diac output, LV ejection fraction, maximal slope of LV systolic pressure
increment (dP/dtmax), maximal slope of diastolic pressure decrement ..
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.. (dP/dtmin) and isovolumetric relaxation constant Tau (IVRc Tau) were
measured and calculated according to standard formulas. Following
the invasive measurements, animals were sacrificed and organ mor-
phometry as well as isolation of LV cardiomyocytes were performed.
Additionally, blood and urine samples were collected for the analysis of
brain natriuretic peptide (BNP) levels, serum creatinine, serum urea,
glomerular filtration rate and proteinuria.
ORM-11035 efficacy and selectivity
The CAS code for ORM-11035 is 786642-16-8, with chemi-
cal name butanamide, 2-amino-N-[6-[(3,4-dihydro-2-phenyl-2H-1-
benzopyran-6-yl)oxy]-3-pyridinyl]-3-methyl-,(2R). The patent number
is WO 2003/006452. The concentration–response relationship for
ORM-11035 on NCX was measured in Sf9 cells stably transfected
with human 1.1 NCX by measuring reverse-mode NCX Ca2+ influx
with Ca2+ indicator Fluo-4. The hERG current concentration response
for ORM-11035 was quantified in HEK293 cells by patch-clamping.
The L-type Ca2+ current concentration response for ORM-11035
was quantified in IMR-32 human neuroblastoma cells measuring
Ca2+ influx by fluorescent Ca2+ indicator (Fluo-4). All experiments
were performed at 37∘C. The fluorescence value, maximum minus
baseline, was calculated for each well with ScreenWorks 2.0 software.
Dose–response curves for the ORM compounds were constructed
from typically a mean of seven separate wells at each of five different
concentrations on a plate. Results are expressed as mean± standard
deviation for number of plates (online supplementary Methods S1).
Cardiomyocyte measurements in the
heart failure with preserved ejection
fraction model
Cardiomyocytes from NXT and Sham rats were isolated from the
same animals that underwent in vivo characterization following enzy-
matic digestion of the explanted Langendorff-perfused heart as pre-
viously described.2 LV cardiomyocytes were loaded with the Ca2+
indicator Fluo-4 AM (Molecular Probes, Leiden, The Netherlands)
and transferred to a confocal line scanning microscope (LSM 510
Meta, Zeiss, Germany). In a subset of cardiomyocytes (only Sham,
NXT and NXT+ORM-11035), LV cardiomyocytes were loaded
with Fura-2AM (1 μmol/L) for [Ca2+]i measurements (excitation at
340/380 nm, emission >510 nm, background corrected) and trans-
ferred to a ratiometric fluorescence microscope setup (Horiba PTI,
Tokyo, Japan, on Zeiss Axiovert microscope, Jena, Germany) addition-
ally equipped with a charge-coupled device camera for edge detec-
tion (cell shortening). Cardiomyocytes were continuously superfused
with superfusion solution and stimulated in an electrical field at both
setups without additional application of ORM-11035 during in vitro
experiments. Ca2+-transient (CaT) amplitude (F, normalized to dias-
tole, F0) and time to half-maximal decay (CaT RT50) were calcu-
lated from confocal line scan images (1.56ms/line along the longi-
tudinal axis of the cell and analysed using custom made algorithms
coded in IDL).4,5 Late diastolic [Ca2+]i (average of 30ms before
stimulus) was quantified ratiometrically, and cell shortening ampli-
tude (percent of resting length) and kinetics (time to 50% relax-
ation, CS RT50) were calculated. All measurements were performed
at 1 Hz steady state (>30 s). For the assessment of sarcoplasmic
reticulum (SR) and NCX Ca2+ transport in intact cardiomyocytes
a superfusion solution with 30mmol/L caffeine for 10 s was applied
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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via a rapid perfusion line (<1 s wash-in) in Fura-2AM-loaded car-
diomyocytes following 1 Hz steady state stimulation. SR Ca2+ con-
tent was quantified as the amplitude of the caffeine-induced Ca2+
transient. Time constant of Ca2+ decay in the presence of caf-
feine (TAUcaff, mono-exponential fit) was quantified as a measure
of NCX forward mode activity. SR Ca2+-ATPase (SERCA)-related
time constant of Ca2+ decay at 1 Hz (TAUSERCA) was calculated
from TAUcaff and tau of the last stimulated CaT (TAUstim), by the
formula: TAUSERCA = 1/(1/TAUstim − 1/TAUcaff). Fractional contribu-
tion of not SERCA-related CaT decay to TAUstim was calculated as
(1/TAUcaff)/(1/TAUstim).
Reporting according to the ARRIVE guidelines
No animals died during the procedure. With an empiric goal of 15–20
cardiomyocytes per group, we chose 4–6 animals per group for isola-
tion of cardiomyocytes. All animals included for cellular measurements
provided at least three cells for analysis. The decision to isolate car-
diomyocytes from an animal was made before the start of the final
experiment (in vivo measurements). Cardiomyocytes that did not com-
plete the full protocol [e.g. 1Hz stimulation at steady state + caffeine
response with rapid (<1 s time to monophasic peak of Ca2+ release)]
or did not follow each stimulus were completely excluded from the
analysis.
Modelling
In order to model NCX current at different [Na]i during the cardiac
cycle, we used the mathematical model for rabbit myocyte electrophys-
iology and Ca2+ dynamics developed by Mahajan et al.6,7
Statistics
Analyses were done using two-way ANOVAs (Figures 1–4; online sup-
plementary Figure S1 and Tables S1–S3) or two-way repeated mea-
sures ANOVA (online supplementary Figure S2) followed by pairwise
comparisons with Bonferroni–Holm correction. One-way ANOVA
with Tukey post-hoc test was used on the subset of ratiometric data
(Figure 5; online supplementary Table S4). An alpha level (P) of 5% was
used for all tests. Data were analysed using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA, USA). Values are given as mean± standard
deviation. Error bars denote standard deviation.
An expanded Material and Methods section is available in the online
supplementary Methods S1.
Results
ORM-11035 selectivity and bioavailability
ORM-11035 concentration–effect curves in vitro yielded an IC50
of 150 nmol/L for NCX (online supplementary Figure S3), 5 μmol/L
for the L-type Ca2+ channel and 1.1 μmol/L for hERG.
Heart failure with preserved ejection
fraction phenotype after subtotal
nephrectomy in rats
Following subtotal NXT, rats showed cardiac remodelling, e.g.
LV hypertrophy [LV mass: 1944± 146 vs. 2581± 208mg; Sham ..
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.. (n = 8) vs. NXT (n =12); P < 0.0001], left atrial enlargement and
diastolic dysfunction with LVEDP elevation [6 ± 2 vs. 14± 3mmHg;
Sham (n = 8) vs. NXT (n = 12); P < 0.0001], increased E/e′ ratio
[19± 2 vs. 31± 3; Sham (n = 8) vs. NXT (n =12); P < 0.0001]
as well as preserved ejection fraction, congestion and increased
BNP levels (Figures 1,2 and online supplementary Tables S1, S2).
Moreover, in cardiomyocytes from untreated NXT rats, early
relaxation was prolonged (Figure 4A, 4E) and NCX-mediated
Ca2+ extrusion was decreased (Figure 5A, 5D) suggesting
increased NCX reverse-mode activity during relaxation in these
HFpEF rats.
Effects of chronic treatment
with ORM-11035 on heart failure
with preserved ejection fraction
phenotype in vivo
NXT rats showed typical signs and symptoms of HFpEF as pre-
viously reported by Primessnig et al.2 This HFpEF-like phenotype
was present at 8weeks following subtotal NXT. ORM-11035
treatment with 1 mg/kg/day was started at week 8 after
NXT/Sham operation and was applied for 16weeks (online
supplementary Figure S4). Long-term chronic treatment with
the novel compound ORM-11035 reversed cardiac remodelling
and diastolic dysfunction in these HFpEF rats (online supple-
mentary Tables S1 and S2). Heart weight/body weight ratio
[3.24± 0.3 vs. 2.81± 0.3 mg/g; NXT (n =12) vs. NXT+ORM
(n = 12); P = 0.004], lung weight/body weight ratio [4.48± 0.56
vs. 3.85± 0.49mg/g; NXT (n =12) vs. NXT+ORM (n =12);
P = 0.02], LV mass, LV relative wall thickness, and left atrial
size [29± 3 vs. 25± 3mm2; NXT (n =12) vs. NXT+ORM
(n = 12); P = 0.003] were significantly reduced after treatment
with ORM-11035 (Figure 1A–F). Treatment with ORM-11035 had
no effect on systolic blood pressure [156± 3 vs. 153± 5mmHg;
NXT (n = 12) vs. NXT+ORM (n =12); P = ns] or diastolic
blood pressure, measured by weekly non-invasive blood pressure
measurements (online supplementary Figure S2) or invasively
at 24weeks during final experiments (Figure 1G and 1H; online
supplementary Table S1). Diastolic dysfunction reflected by LVEDP
[14± 3 vs. 9 ± 2mmHg; NXT (n = 12) vs. NXT+ORM (n =12);
P = 0.0002], IVRc Tau [9.5 ± 0.6 vs. 8.7 ± 0.8 ms; NXT (n =12) vs.
NXT+ORM (n = 12); P = 0.006] as well as E/e′ [31± 3 vs. 24± 2;
NXT (n = 12) vs. NXT+ORM (n =12); P < 0.0001] and BNP
levels [71± 12 vs. 49±11 pg/mL; NXT (n =12) vs. NXT+ORM
(n = 12); P < 0.0001] were significantly reduced after chronic
treatment with ORM-11035 in NXT (Figures 2A,2B,2E, 3A–C)
while LV ejection fraction and heart rate (Figure 2C and 2D) were
unchanged.
Improved renal function after long-term
treatment with ORM-11035
Renal function was significantly improved in NXT rats after
treatment with ORM-11035 for 16weeks. Serum creati-
nine [78.56±12.87 vs. 55.96± 8.27 μmol/L; NXT (n = 12)
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Effects of long-term chronical treatment with ORM-11035 on cardiac remodelling and systemic blood pressure in heart failure with
preserved ejection fraction rats. (A) Heart weight/body weight ratio, (B) lung weight/body weight ratio, (C) left atrial size, (D) left ventricular
mass, and (E) left ventricular relative wall thickness are significantly reduced in nephrectomy (NXT)+ORM-treated animals compared to
untreated NXT rats. (F) Echocardiographic M-mode images of the left ventricle in Sham and NXT-treated or untreated with ORM. (G) Systolic
blood pressure and (H) diastolic blood pressure are not affected after ORM treatment in Sham and NXT animals. Symbols = animals. Data are
mean± standard deviation. Analysis using two-way ANOVA. Groups are Sham (n = 8), Sham+ORM (n = 8), NXT (n =12) and NXT+ORM
(n = 12). IVS, interventricular septum; LVEDD, left ventricular end-diastolic diameter; PW, posterior wall.
vs. NXT+ORM (n = 12); P < 0.001] and serum urea were
significantly reduced while glomerular filtration rate (19± 2
vs. 24± 3 mL/min; NXT (n = 12) vs. NXT+ORM (n =12);
P < 0.0001] significantly improved after long-term admis-
sion of ORM-11035. Additionally, serum sodium, potassium,
and proteinuria [3.16± 1 vs. 2.01± 0.7 g/L; NXT (n = 12)
vs. NXT+ORM (n =12); P = 0.009] were reduced in
NXT rats treated with ORM-11035 (online supplementary
Table S1). ..
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.. ORM-11035 improves cardiomyocyte
relaxation and cytosolic Ca2+ decay
Left ventricular cardiomyocyte cell shortening amplitude tended
to be lower in NXT vs. Sham animals (Figure 4A and 4C; online
supplementary Table S3). ORM-11035 did not significantly alter
contraction amplitude in Sham or NXT (Figure 4A and 4C; online
supplementary Table S3). ORM-11035 significantly accelerated
relaxation time (CS RT50) in NXT [73.1 ± 24.8 vs. 47.5 ±14.2 ms;
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Chronic treatment with ORM-11035 reduces E/e′ and brain natriuretic peptide (BNP) levels while heart rate and left ventricular
ejection fraction are unchanged in heart failure with preserved ejection fraction (HFpEF) rats. (A) Examples of tissue Doppler measured e′ in
Sham and nephrectomy (NXT) animals treated or untreated with ORM. (B) Echocardiographic measured E/e′ shows a significant reduction after
ORM treatment in HFpEF rats. (C) Left ventricular ejection fraction and (D) heart rate are unchanged after ORM admission in Sham and NXT
rats. (E) BNP levels are significantly reduced in NXT + ORM-treated HFpEF rats compared to untreated animals. Symbols = animals. Data are
mean± standard deviation. Analysis using two-way ANOVA. Groups are Sham (n = 8), Sham+ORM (n = 8), NXT (n =12) and NXT+ORM
(n = 12).
NXT (n = 22) vs. NXT+ORM (n = 15); P = 0.0003] (Figure 4A and
4E; online supplementary Table S3). More rapid cell re-lengthening
in vitro correlated with reduced LVEDP in the same animals in
vivo (Figure 3D). In analogy to cell shortening amplitude, the
amplitude of LV cardiomyocyte Ca2+ transients were slightly but
significantly decreased in NXT vs. Sham rats, while no significant
difference was observed in ORM-11035-treated vs. untreated
NXT animals (Figure 4B and 4D; online supplementary Table S3).
Ca2+ removal from the cytosol (CaT RT50) was slowed in NXT
vs. Sham. ORM-11035 had no effect on cytosolic Ca2+ removal in
Sham but significantly accelerated prolonged Ca2+ removal in NXT
[CaT RT50: 171.8 ± 36 vs. 130.6 ± 32.5 ms; NXT (n = 16) vs.
NXT+ORM (n = 18); P = 0.002] (Figure 4B and 4F; online supple-
mentary Table S3). Concurrent, TAU of the CaT was prolonged in
NXT vs. Sham and significantly ameliorated in ORM-11035-treated
NXT animals (Figure 4F; online supplementary Table S3).
Ratiometric measurements revealed unchanged end-diastolic ..
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.. [Ca2+]i (Figure 5B). SR calcium content was decreased in NXT vs.
Sham animals but was not affected by ORM treatment (Figure 5C;
online supplementary Table S4). During caffeine application,
cytosolic Ca2+ removal attributed to NCX (forward mode) was
significantly slower in NXT vs. Sham. Chronic ORM-11035 treat-
ment significantly ameliorated the slowed non-SERCA-dependent
cardiomyocyte Ca2+ extrusion in NXT (Figure 5A and 5D; online
supplementary Table S4). The SERCA-related cytosolic Ca2+ decay
constant during electrical stimulation (TAUSERCA), as calculated
from TAUstim and TAUcaffeine, was prolonged in NXT and restored
in NXT+ORM (Figure 5F). In addition, the calculated contribu-
tion of not SERCA-related decay to the electrically stimulated
Ca2+ transient was reduced in NXT vs. Sham (Figure 5G) with
variable but non-significant change in NXT+ORM. In summary,
LV cardiomyocytes from chronically ORM-treated rats showed
improved active relaxation and diastolic cytosolic Ca2+ decay as
well as restored NCX-mediated Ca2+ removal.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 ORM-11035 attenuates diastolic dysfunction in heart failure with preserved ejection fraction rats. (A) Example pressure–volume
loop recordings from nephrectomy (NXT)+ORM (gray) and NXT untreated (black) animals. (B) Chronic treatment with ORM for 16weeks
attenuates (B) left ventricular end-diastolic pressure (LVEDP) and (C) left ventricular (LV) relaxation constant TAU. Symbols = animals. Data
are mean± S.D. P – values. Analysis using two-way ANOVA. Groups are Sham (n = 8), Sham+ORM (n = 8), NXT (n = 12) and NXT+ORM
(n = 12). (D) Rapid cell re-lengthening (CS RT50) in vitro correlated with reduced LVEDP in the same animals in vivo (NXT and NXT+ORM).
Symbol = cell average/heart.
Role of altered Na+/Ca2+ exchanger
and SERCA activity and increased [Na+]i
for cytosolic Ca2+ decay in a
mathematical cell model
We explored the effects of altered NCX and SERCA activity
on cytosolic Ca2+ and Na+ in a mathematical rabbit myocyte
model. As shown in the online supplementary Figure S1A, a
reduction of SERCA activity to 75% of control and increased
NCX activity lead to a slowed Ca2+ transient decay mimicking
the changes observed in the present HFpEF model. Increased
NCX activity leads to a small increase in cytosolic [Na+]i (online
supplementary Figure S1B). In another simulation (online sup-
plementary Figure S1C) we assumed a stronger elevated [Na+]I,
which then induces reduced overall NCX forward mode activity
(lower integral) and a leftward shift of the peak forward mode ..
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. activity. Ca2+ transients in NXT combining increased [Na+]i (20
vs. 14mM in control), increased NCX activity (>50% of control)
and reduced SERCA (80% of control). Inhibition of NCX and
restoration of SERCA activity with ORM improves diastolic Ca2+
decay. (Figure 3D)
Discussion
In the present study, chronic treatment with the novel NCX
inhibitor ORM-11035 was effective in ameliorating signs and symp-
toms in a rat model of manifest cardiorenal HFpEF. In addition,
we demonstrate that the beneficial effects of this specific NCX
inhibitor on myocardial function and remodelling are independent
of the blood pressure-lowering effect previously observed in vivo
with SEA0400,2 which implies that treatment of HF in vivo involves
improvement of intrinsic cardiomyocyte function.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 ORM-11035 accelerates contraction and cytosolic Ca2+ decay in left ventricular cardiomyocytes from nephrectomy (NXT)-treated
rats. Representative example of cell shortening (A) and cytosolic Ca2+ transients (B; confocal; Fluo-4 AM) at 1 Hz in cardiomyocytes from Sham,
NXT and NXT+ORM. Left ventricular cardiomyocyte cell shortening amplitude tended to be lower and Ca2+ transient (CaT) amplitude was
lower in NXT vs. Sham-treated animals (C, D). Contraction and CaT amplitudes in Sham as well as in NXT were not affected by ORM. (B)
Time to half-maximal cardiomyocyte relaxation (CS RT50) and time to half-maximal cytosolic CaT decay were significantly prolonged in NXT
vs. Sham (E, F). ORM significantly accelerates relaxation time (CS RT50) and CaT decay in NXT. Symbols = individual cardiomyocytes. Groups
were Sham (n = 15 cells from n = 4 animals), Sham+ORM (n =15; n = 5), NXT (n = 22; n = 6) and NXT+ORM (n = 15; n = 4). Analysis
using two-way ANOVA.
HFpEF is an increasingly commonly diagnosed clinical mani-
festation of various systemic disease entities resulting in cardiac
involvement with diastolic dysfunction.1 Chronic kidney disease
with moderately to severely impaired renal function is observed in
almost half of HFpEF patients and renal dysfunction may be pivotal
in an even larger fraction of patients with HFpEF.8,9 Management
of HFpEF is currently limited to symptomatic therapy of conges-
tion using diuretics and treatment of associated co-morbidities.
Targeting classical pathways over-activated in HF with reduced
ejection fraction (HFrEF) such as the renin–angiotensin system
or beta-blockade generally have not been effective.10 It has been
proposed that the cellular mechanisms underlying HFrEF (with
progressive loss of cardiomyocytes) are fundamentally different
from HFpEF, where inflammation and endothelial dysfunction trig-
ger cardiomyocyte dysfunction, mainly due to increased passive
stiffness.11 Previously, we and others have shown that active, i.e. ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Ca2+-dependent, cardiomyocyte relaxation contributes to diastolic
dysfunction in HFpEF.2,12 Cytosolic Ca2+ decay in physiological con-
ditions is mediated mainly by SERCA-dependent Ca2+ reuptake
into the SR and to a lesser extent by the sarcolemmal NCX. NCX
works in forward (Ca2+ out, Na+ in) or reverse mode depending
on local (subsarcolemmal) ion concentrations and NCX regulation,
and several changes in direction during the normal action poten-
tial may occur.13 Several mechanisms may be involved in alteration
of NCX-dependent cytosolic Ca2+ removal in this HFpEF model.
The cellular phenotype is characterized by a slowed diastolic Ca2+
decay without signs of cellular Ca2+ overload, as in NXT diastolic
Ca2+ is unchanged and SR Ca2+ content is decreased. NCX pro-
tein expression is increased,2 suggesting increased NCX activity.
Slowed cytosolic Ca2+ decay can be explained by reduced SERCA
activity (Figure 5F; online supplementary Figure S1A), but may also
involve increased NCX activity in reverse mode during the phase
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 5 ORM-11035 improves Na+/Ca2+ exchanger (NCX)- and sarcoplasmic reticulum Ca2+-ATPase (SERCA)-related cytosolic Ca2+
removal. (A) Representative examples of electrically stimulated cytosolic ratiometric Ca2+ transients (1 Hz steady state; Fura-2 AM) followed
by a caffeine-induced Ca2+ transient in Sham, nephrectomy (NXT) and NXT+ORM. Mean values for end-diastolic [Ca2+]i (B), sarcoplasmic
reticulum Ca2+ content (C), decay of the caffeine-induced (D) and electrically-induced (E) Ca2+ transient. The SERCA-related (F) and not
SERCA-related (G) contributions to cytosolic [Ca2+]i decay at 1 Hz were calculated from (D) and (E) (see Methods for details). Groups were
Sham (n =15 cells from n = 5 animals), Sham+ORM (n = 15; n = 6), NXT (n = 22; n = 6) and NXT+ORM (n = 14; n = 4). Analysis using
one-way ANOVA.
of relaxation, as observed with increased intracellular [Na]i and
contributing to diastolic dysfunction in HFrEF.14,15 While limited
by species differences (rabbit vs. rat), our simulations in a math-
ematical cell model similarly indicate that an increase in [Na+]I
may indeed shift the timing of NCX forward mode activity dur-
ing the cardiac cycle leading to reduced forward mode activity
during cardiomyocyte relaxation, supporting a role for increased
[Na+]i sensed by NCX in the observed cardiomyocyte pheno-
type (online supplementary Figure S1C). While [Na+]i may enhance
NCX reverse mode and decrease forward mode, the net effect of
the NCX has to be extrusion of external Ca2+ entering via the
L-type Ca2+ channels to maintain a steady state over the whole car-
diac cycle.16 Several sources of excess [Na+]i may be conceivable:
(i) increased NCX activity per se may be responsible for increased
Na+ influx and thus [Na]I, which at a later phase of the cardiac cycle
(depending on the transsarcolemmal membrane potential) may
then trigger increased reverse-mode activity; (ii) increased Ca2+
influx through other channels (e.g. L-type Ca2+ or transient recep-
tor potential channels) accumulating Na+ via forward-mode NCX
in NXT animals. Based on our data, however, we consider this
unlikely as increased transsarcolemmal Ca2+ influx in combination
with NCX inhibition with ORM-11035 would aggravate diastolic
Ca2+ load, which is not what we have observed; (iii) increased Na+
load through other channels which in the presence of ORM-11035
would no longer be translated into increased [Ca2+]i. transient
receptor potential channels, the late Na+ current, sodium–proton
exchanger and reduced Na+/K+-ATPase (NKA) activity have been
described as sources for increased [Na+]i in remodelled cardiomy-
ocytes. Interestingly, in the present model, protein expression of ..
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. the NKA alpha1 and alpha2 isoforms was significantly reduced in
NXT2 (Figure 5E and 5F).
At the cardiomyocyte level, in HFpEF animals, chronic treat-
ment with ORM-11035 induced alterations in cytosolic Ca2+
handling, which are not readily explained by inhibition of NCX
alone. This is not unexpected as intracellular Ca2+ in cardiomy-
ocytes is highly controlled by feedback mechanisms, and even very
specific modulation of one target will affect several regulators
of intracellular Ca2+.17,18 Indeed, the more rapid diastolic Ca2+
removal with ORM-11035 (Figures 4F and 5E) not only improved
non-SERCA-dependent Ca2+ removal during caffeine application
usually attributed to NCX (Figure 5D), but also significantly accel-
erated the SERCA-related decay of the stimulated Ca2+ transient
(Figure 5F). The calculated not SERCA-related decay of the stim-
ulated Ca2+ transient in NXT+ORM was more variable and not
significantly different fromNXT. The cause of this additional degree
of variation is not clear; however, the difference in the directly
measured not SERCA-related decay constant during the caffeine
response between NXT and NXT+ORM was highly significant
and underscores the altered role of not SERCA-related decay fol-
lowing ORM-11035 treatment. As neither diastolic [Ca2+]i nor SR
[Ca2+]i were affected by chronic ORM-11035, a reduction of Ca
2+
influx by functional inhibition of the L-type Ca2+ channel by sub-
sarcolemmal Ca2+ may act as compensatory as has been shown in
NCX1 knock-out mice.19 The relevance of ORM-11035 for excess
sodium via the NCX and a phase shift in NCX forward-mode activ-
ity in HFpEF needs to be explored in future studies.
In summary, specific chronic NCX inhibition triggered adap-
tation of the highly controlled intracellular Ca2+ balance and
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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cardiomyocyte phenotype that contributed to improved cardiac
function in vivo.
Irrespective of the origin of ionic dysbalance, we have shown
previously that in the present HFpEF model NCX forward-mode
activity during diastole is reduced and that the NCX inhibitor
SEA0400 improves diastolic Ca2+ decay.2 NCX inhibition may
provide a therapeutic target. This is in line with the beneficial effects
of NCX inhibition in other conditions of increased cardiomyocyte
Ca2+ load such as myocardial ischaemia/reperfusion damage and
Ca2+-mediated arrhythmias.20,21
However, within a magnitude of commonly used dosage,
SEA0400 also acts on other ion channels, mainly L-type Ca2+
channels,22,23 and KB-R7943, another commonly used NCX
inhibitor, does not allow for higher specificity.24 Recently, several
novel orally available NCX inhibitors with significantly higher
specificity than SEA0400 have been introduced and proved bene-
ficial to treat experimental arrhythmias.20,21 In the present study,
ORM-11035, a derivative of ORM-10103, showed a 30-fold
higher sensitivity to NCX than L-type Ca2+ channels, confirming
a much higher specificity for NCX than SEA0400 or KB-R7943
and no apparent effects on cardiac action potential. Systemic
blood pressure, which is elevated early as one trigger of cardiac
dysfunction and HFpEF in this model, was also not affected.
SEA0400 on the other hand has been shown to decrease2,25 or
increase26,27 systemic blood pressure. Blood pressure-lowering
effects may also be mediated by (renal) vascular NCX1 in some
models of hypertension.25 However, as in the present model with
comparable effect on cardiac remodelling SEA0400 reduced blood
pressure but ORM-11035 did not, we conclude that this reflects
higher specificity of ORM-11035.
We have chosen to study cardiomyocyte function from chroni-
cally ORM-11035-treated animals in the absence of ORM-11035 in
vitro. A limitation is that additional acute effects of therapeutic levels
of ORM-11035 on cardiomyocyte function may not be picked up in
the in vitro experiments. However, this approach allowed us to com-
pare the chronic adaptation of intrinsic cardiomyocyte contractility
and Ca2+ using identical standardized conditions in all groups. A
good in vitro/in vivo correlation of diastolic function confirmed that
the beneficial effects of ORM-11035 on cardiomyocyte function
reflected improved function in vivo.
Interestingly, in the present study, chronic NCX inhibition with
ORM-11035 also improved maladaptive hypertrophic myocardial
remodelling in HFpEF rats in vivo. We and others have previously
shown that chronically increased diastolic cardiomyocyte Ca2+
load can be a trigger of cardiomyocyte hypertrophy.28 Thus, a
reduction in cardiomyocyte Ca2+ load with ORM-11035 may have
contributed to reverse remodelling in HFpEF rats in the present
study. In addition, myocardial dysfunction in HFpEF is often asso-
ciated with increased fibrosis. In the present model as well as
in a rat model of hypertensive HFpEF (Dahl salt-sensitive rats)
amelioration of HFpEF following NCX inhibition with SEA0400
was associated with reduced myocardial fibrosis.2,12 A similar pre-
ventive effect of NCX inhibition with SEA0400 was observed
when myocardial fibrosis was triggered by increased reverse-mode
NCX activity following chronic ouabain treatment in rats,12 ..
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.. corroborating a role for reverse-mode NCX in cardiomyocyte dys-
function and increased fibrosis in HFpEF.
Study limitations
As reported here and previously,2 the current model reflects
many features of clinical HFpEF. However, contribution of NCX to
cytosolic Ca2+ transients may differ in larger animals and humans. In
addition, the efficacy of NCX inhibition may vary in HF of different
aetiologies. While published data suggest a stronger role for NCX
in larger animals, and predominantly reverse-mode NCX (Ca2+
intrusion) has been observed in human HFrEF,14 the role of NCX
inhibition with ORM-11035 in human diseased myocardium needs
to be confirmed.
Conclusion
ORM-11035 improves cardiac remodelling and contractile func-
tion in a cardiorenal model of HFpEF. Our results indicate
that novel, more specific NCX inhibitors do not only provide
benefit in Ca2+-mediated arrhythmias as reported earlier but
may also provide a promising approach to treat HF. Improve-
ments in cardiac function and remodelling are observed in the
absence of blood pressure-lowering effects. Thus, specific NCX
inhibitors may provide a therapeutic approach to improve car-
diac function and myocardial remodelling in cardiorenal HFpEF
patients.
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